Curis Inc. (CRIS)

1.63
0.00 (0.00)
NASDAQ : Health Technology
Prev Close 1.63
Open 1.61
Day Low/High 1.59 / 1.71
52 Wk Low/High 0.60 / 2.65
Volume 105.45K
Avg Volume 559.00K
Exchange NASDAQ
Shares Outstanding 33.15M
Market Cap 55.03M
EPS -1.00
P/E Ratio N/A
Div & Yield N.A. (N.A)
Short Interest Surges 170.7% For CRIS

Short Interest Surges 170.7% For CRIS

The most recent short interest data has been released by the NASDAQ for the 07/15/2015 settlement date, which shows a 2,876,441 share increase in total short interest for Curis Inc , to 4,561,545, an increase of 170.70% since 06/30/2015. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Curis (CRIS) Is Strong On High Volume Today

Curis (CRIS) Is Strong On High Volume Today

Trade-Ideas LLC identified Curis (CRIS) as a strong on high relative volume candidate

Curis Reports First Quarter 2015 Financial Results

Curis Reports First Quarter 2015 Financial Results

Management to Host Conference Call Today at 8:30 a.m. EDT

Curis Presents Preclinical Data On CUDC-427 At AACR Annual Meeting

Curis Presents Preclinical Data On CUDC-427 At AACR Annual Meeting

Collaborator Aurigene Presents Data From Its IRAK-4 Program

Curis (CRIS) Is Strong On High Volume Today

Curis (CRIS) Is Strong On High Volume Today

Trade-Ideas LLC identified Curis (CRIS) as a strong on high relative volume candidate

Develop Biotech 'Buy-Sell' Strategy

Develop Biotech 'Buy-Sell' Strategy

When to take profits is a tricky but important decision.

Strong On High Relative Volume: Curis (CRIS)

Strong On High Relative Volume: Curis (CRIS)

Trade-Ideas LLC identified Curis (CRIS) as a strong on high relative volume candidate

Get Off the Energy Roller Coaster

Get Off the Energy Roller Coaster

Try these two small biotechs with no connection to the gyrations of energy markets.

Curis Announces Dosing Of First Patient In Phase 1 Trial Of CUDC-907 In Patients With Advanced/ Relapsed Solid Tumors

Curis Announces Dosing Of First Patient In Phase 1 Trial Of CUDC-907 In Patients With Advanced/ Relapsed Solid Tumors

-- Trial Expected to Enroll Patients With Hormone Receptor Positive Breast Cancer and Patients With Midline Carcinoma With NUT Rearrangement --

TheStreet Quant Rating: D- (Sell)